SDK1 as an Independent Prognostic Biomarker in Primary Glioma: A Multi-Cohort Validation Study with Functional Characterization.

Int J Mol Sci · 2026 · PMC13207070 · PMID 42196180

Europe PMC DOI

hedged sentences

0.5060

closest p · 10.1× alpha

0.6520

boldest claim

The sentences

failed to reach statistical significancep = 0.506not close (p > 0.1)

Fifth, our subgroup analyses revealed that SDK1’s prognostic impact is not uniform across all histologies; it failed to reach statistical significance in WHO grade II gliomas (HR = 1.28, 95% CI 0.62–2.63, p = 0.506) and in several other subgroups.

also in 6,035 other papers

did not reach statistical significancep = 0.652not close (p > 0.1)

SDK1 did not reach statistical significance in patients aged ≥ 60 years (HR = 1.13, 95% CI 0.66–1.95, p = 0.652), WHO grade II tumors (HR = 1.28, 95% CI 0.62–2.63, p = 0.506), WHO grade III tumors (HR = 1.60, 95% CI 0.99–2.58, p = 0.053), or MGMT-methylated tumors (HR = 1.31, 95% CI 0.91–1.88, p = 0.149).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.